Autolus

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities and capital required to manufacture, develop and commercialise its programmed T cell product candidates.

Autolus is a leader in T cell programing, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care. Autolus is a leader in T cell programing, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.